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S~mlTlary 
The use of monodonal antibodies (mAbs) directed to lipid A for the therapy of gram-negative 
sepsis is controversial.  In an attempt to understand their biologic basis of action, we used a fluid- 
phase radioimmunoassay to measure binding between bacterial lipopolysaccharide (LPS) and two 
IgM mAbs directed to lipid A that are being evaluated for the treatment of gram-negative  bacterial 
sepsis. Both antibodies bound 3H-LPS prepared from multiple strains of gram-negative bacteria 
when large excesses of antibody were used, although binding was modest and only slightly greater 
than control preparations. We also studied the ability of each anti-lipid A antibody to neutralize 
some of the biological effects of LPS in vitro. Despite large molar excesses, neither antibody 
neutralized LPS as assessed by the limulus lysate test, by a mitogenic assay for murine splenocytes, 
or by the production of cytokines interleukin (IL)-I, II.-6, or tumor necrosis factor from human 
monocytes in culture medium or in whole blood. Our experiments do not support the hypothesis 
that either of these anti-lipid A  mAbs function by neutralizing the toxic effects of LPS. 
I 
n 1968, Chedid et al. (1) reported that the passive infusion 
of antiserum raised to killed rough mutant bacteria pro- 
tected mice against challenge with heterologous gram-negative 
bacteria. Rough mutant bacteria  are unable to incorporate 
O-polysaccharide onto the glycolipid of LPS, and therefore 
expose the deeper core structures of endotoxin on their sur- 
face. These authors proposed that a few antibodies or serum 
factors specific for the endotoxin core could "have the capa- 
bility of coping, like masterkeys, with a very wide range of 
infections due to serologically unrelated organisms" (1). Over 
the next two decades, several laboratories studied the ability 
of antisera raised to two bacterial mutants, Escherichia coli J5 
and Salmonella minnesota Re595, to protect in animal models 
of endotoxic shock. Most (1-7), but not all (8, 9), of these 
studies confirmed that passively transferred antisera raised to 
these organisms protect against challenge with heterologous 
LPS in animal models. A clinical trial indicated that poly- 
clonal antiserum raised to E. coli J5 was therapeutic for pa- 
tients with gram-negative sepsis (10). Two lines of evidence 
suggested that the protective element in these antisera was 
Ig directed against common epitope(s). First, purified Ig frac- 
tions prepared from the polyclonal antisera protected in an- 
imal models (4,  11,  12). Second, the protective activity in 
the antisera could be adsorbed with the rough mutant LPS 
or bacteria, but not with control heterologous LPS or bac- 
teria (1, 5, 6, 13, 14). The concept evolved that some of the 
Ig in these antisera cross-reacted  with LPS from multiple gram- 
negative strains,  and therefore was able to "cross-protect" 
against heterologous strains. Cross-reactive Ig was hypothe- 
sized to protect by neutralizing the toxic effects of endo- 
toxin (10). 
Several investigators have generated mAbs to structures on 
the core glycolipid of LPS (15-20).  Two of these,  HA-1A 
(Centocor, Malvern, PA) and E5 (XOMA, Berkeley, CA), 
have been studied in human trials  which enrolled patients 
with suspected gram-negative sepsis (16, 21, 22). HA-1A is 
a human IgM mAb that binds to lipid A (15). This antibody 
has been reported to protect in some animal models (15, 
23), although in other models, the protection has been only 
modest (24, 25). The protective efficacy of HA-1A for gram- 
negative sepsis has been studied in a single double-blind, ran- 
domized, placebo-controlled clinical trial (21). In this study, 
administration of HA-1A was associated with decreased 28-d 
all-cause mortality in a subgroup of patients that had gram- 
negative bacteremia.  HA-1A is licensed for use as a therapy 
for gram-negative sepsis in some countries in Europe. E5 is 
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are few data available regarding the ability of E5 to protect 
in animal models. Two articles suggest that it provides slight 
protection against endotoxin (26) or bacterial challenge (27). 
E5 has been evaluated in two clinical trials. In the first trial, 
administration of E5 was associated with increased survival 
in a subset of patients with gram-negative sepsis who were 
not in refractory shock (16). In the second trial, there was 
apparently no improved survival in patients with documented 
gram-negative sepsis, although these results have been pre- 
sented in abstract form only (22). 
Because a proposed mechanism of action of these two an- 
tibodies is to bind and neutralize LPS, we studied the ability 
of each to bind the LPS from multiple clinical strains of gram- 
negative bacteria. The results of solid-phase  immunoassays 
can be difficult to interpret because  of nonspecific interac- 
tions and the amphipathic nature of LPS. Accordingly, we 
used a fluid-phase RIA to measure antibody-LPS binding. 
We also evaluated the ability of each anti-lipid A antibody 
to neutralize the effects of LPS in several in vitro assays of 
endotoxin bioactivity. We found that both HA-1A and E5 
bound slightly to LPS from multiple smooth strains of gram- 
negative bacteria when large excesses of antibody were used. 
However, neither antibody neutralized LPS as assessed by the 
limulus lysate test, by a mitogenic assay for murine spleno- 
cytes,  or by the production of the cytokines IL-1, Ib6,  or 
TNF from human monocytes in culture medium or in whole 
blood. Our experiments do not support the hypothesis that 
either of these two anti-lipid A mAbs function by binding 
and neutralizing the toxic effects of LPS. 
Materials and Methods 
LPS 
Unlabeled LPS from Salmonella t~himuriurn, Klebsiella pneumo- 
niae, Sermtia marcescens, E. coli J5, and E. coli K12,D31m4 (Re) were 
purchased from List Biol. Laboratories, Inc. (Campbell, CA). Un- 
hbeled LPS from E. coli 0113 was prepared by the hot phenol method 
as described  by Pmdbach et al. (28). Unlabeled LPS from Neisseria 
raeninsitidis  was the kind gift of Martine Caroff (Unit6 Associte 
Centre National de la Recherche  Scientifique  1116, Orsay, France). 
Cultures of E. coli 0111:B4, E. coli 018, and E. coli J5 were the 
kind gifts of Dr. David Morrison (University of Kansas Medical 
Center, Kansas City, KS), Dr. George Siber (Dana Farber Cancer 
Institute, Boston, MA), and Dr. Jerald Sadoff  (Walter Reed Army 
Institute of Research, Washington, DC), respectively.  Cultures of 
E. coti strains 01, 02, 04, 06, 07, 08, 016, 025, and 075 were the 
kind gifts of Dr. Alan Cross (Walter Reed Army Institute of Re- 
search). 
Biosynthetically  radiolabeled strains orE. coli strains (except for 
E. coliJS) were prepared by growing the organisms in the presence 
of [3H]acetate followed  by hot phenol extraction as previously  de- 
scribed (29). Briefly,  we grew cultures of each organism to an OD 
of 0.9 at 540 nm (with a path length of 1.0 cm) in broth con- 
taining, per liter, 22.5 g of  yeast extract, 11 g peptone, 4 g of  mono- 
basic potassium phosphate, 16.8 g of  diabasic  potassium phosphate, 
and 10 g of glucose, in the presence of 10 mCi of [3H]acetate per 
100 ml broth.  The cells were chilled and washed three times in 
saline, and the LPS was extracted by the hot phenol method (30). 
The preparations were then treated with DNase and KNase and 
then with pronase (Sigma  Chemical  Co., St. Louis,  MO) according 
to the method of Romeo et al. (31). The concentrations of LPS 
were estimated by a spectrophotometric limulus amoebocyte  lysate 
(LAL)  1 gelation assay using an E.  coli Ol13  LPS standard con- 
taining  10 endotoxin  U/ng (lot  20;  Associates of Cape Cod, 
Falmouth, MA) 02). These results were similar to those obtained 
by weight. Solutions of [3H]LPS were adjusted to 1 #g/ml and 
cpm/#g were calculated by counting a 0.4-ml volume combined 
with 4.5 ml of  optiflor scintillation fluid (Packard Instrument Co., 
Downers Grove, 1L). The different LPS contained the following 
cpm//xg: E. coli O1, 7,110; E. coli 02, 13,810; E. coli 04, 10,490; 
E. coli 06, 7,200; E. coli 07, 12,150; E. coli 08, 10,990; E. coli 
O16, 17,100; E. coli O18, 6,150; E. coli 025, 11,040; E. coli 075, 
4,700; andE. coli Ol11:B4, 4,040. Greater than 99% of  each radio- 
labeled LPS was demonstrated to remain in the water phase after 
1:1 ether/water extraction at pH 5. SDS-PAGE of  each  LPS resulted 
in a regularly spaced  band pattern typical  of  LPS when stained  with 
silver. Similar regularly spaced band patterns were obtained when 
the gels were analyzed by autoradiography. 
Radiolabded LPS from E. coli J5 was made by growing the or- 
ganisms in broth containing [3H]acetate as described above, and 
extracting the LPS as described by Galanos et al. (33). This LPS 
contained 22,000 cpm/#g. 
Antibodies  and  Controls 
The human anti-lipid A IgM mAb (HA-IA, Centoxin) used 
in the study was from Centocor B.V. (Leiden, The Netherlands). 
It was supplied as a 5 mg/ml solution containing 5% human serum 
albumin. Murine anti-lipid A IgM mAb (E5) was the kind gift 
of Dr.  Robert  Kubin  (Infectious Disease Unit,  Massachusetts 
General Hospital). It was supplied as a 2 mg/ml solution in PBS, 
pH 7.3. Murine IgG2a mAb directed to the O-polysaccharide  of 
E.  coli  Olll:B4  was  the  kind  gift  of Dr.  Matthew  Pollack 
(Uniformed  Health  Services University  and  Health  Sciences, 
Bethesda, MD). Human myeloma  IgM and murine polyclonal  IgM 
were purchased from Rockland Inc. (Gilbertsville,  PA). Polyclonal 
human IgM was purchased from Organon Teknika Corp. (West 
Chester, PA). Polymyxin  B used in the mitogenic experiments and 
the cytokine experiments were obtained from Pfipharmes (New 
York, NY). 
Fluid-phase  RIA 
Radiohbeled LPS was incubated in dilutions of each mAb or 
controls at 37~  Complexes of [3H]LPS bound to protein were 
then separated from free [3H]LPS by precipitation in half-saturated 
ammonium sulfate according to the method of Farr (34). 
Specifically, 5/zg/ml of each smooth LPS tested was incubated 
in 150/A of dilutions of the mAb to be tested in .01 M PBS, pH 
7.3 for 120 n'fin at 37~  in a 1.5-ml microcentrifuge tube. Con- 
trois were human serum albumin (HSA), polyclonal  human IgM, 
human myeloma IgM, polydonal murine IgM, and a marine IgG 
mAb directed to the O-polysaccharide of E.  coli Ol11:B4. After 
incubation, the solution was cooled on ice for 15 min. An equal 
volume of iced saturated ammonium sulfate was then added drop- 
wise and the solution was allowed to sit at 4~  for another 15 
min. The tubes were next centrifuged at 12,000 g for 15 min. Su- 
pernatants were carefully  aspirated, and pellets were washed twice 
with 50% ammonium sulfate and resuspended in 300/zl of PBS. 
1 Abbreviations used in  this paper: HSA, human serum albumin; LAL, 
limuhs amoebocyte  lysate. 
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by counting 0.4 ml of a 1:7 dilution of each combined with 4.5 
ml ofoptiflor scintillation fluid (Packard Instrument Co.). Quench- 
ing was minimal and was corrected by using the internal standard 
method. Greater than 99% of the HA-1A was documented to be 
in the pellet after precipitation with 50% ammonium sulfate as 
assessed by a capture IgM ELISA technique. Greater than 80% of 
E5 was found in the pellet after precipitation as assessed by a pro- 
tein assay using bicinchoninic acid  (Pierce  Chemical Co., Rock- 
ford, IL). Less than 5% of each smooth LPS tested precipitated 
in PBS alone.  However, >90%  of the [3H]LPS from rough mu- 
tant E. coliJ5 precipitated in PBS-HSA alone, so that we were un- 
able to test this LPS in the system. For most oftbe assays, recovery 
of radioactivity was >85%  using this assay. At low protein con- 
centrations (<50/~g/ml), recovery was sometimes less, which we 
attributed to LPS binding to the walls of the tube. All assays were 
performed in duplicate and the results are given as means. Results 
were calculated as percent recovered cpm as determined by the for- 
mula:  100￿  (cpm in the pelht/cpm recovered), expressed to the 
nearest whole percentage point. Results are given as the mean of 
at least two experiments. 
LAL Assay 
A spectmphotometric LAL assay was used as previously described 
(35).  Briefly,  50/~1 of a  solution of 20/zg/ml  of each mAb in 
pyrogen-free saline were incubated with 50 #1 of dilutions of LPS 
for 30 rain at 37~  in a 96-well microtiter plate. 100/zl of LAL 
were then added, and the plate was incubated at 37~  for an addi- 
tional  60  rain.  Coagulation  of the  LAL  was  measured  spec- 
trophotometrically at OD~  in an automated ELISA reader.  Co- 
agnlation of the LAL in the presence of HA-1A or E5 was compared 
with coagulation of the LAL in saline  alone. 
Mitogenic Assay 
The mitogenic assay was performed essentially as described by 
Jacobs et al.  (36).  Briefly, dilutions of LPS were preincubated in 
the presence of 625/~g/ml  mAb or control,  or 50/~g/ml poly- 
myxin B for 2 h at 37~  This solution was then diluted in RPMI 
media supplemented with antibiotics containing 0.01 M Hepes and 
10% FCS and incubated in a volume of 200/~1 for 48 h with 5  x 
106 spleen  cells from BALB/c mice. The final  antibody or HSA 
control concentrations in culture were 25/~g/well and the final 
polymyxin B concentration in culture was 2/zg/weU.  1 IzCi of 
[~H]thymidine was next added  to each well,  and cells were in- 
cubated for an additional 16 h. Incorporated radioactivity was mea- 
sured using a cell harvester (Cambridge Technology, Inc., Water- 
town, MA) to disrupt the cells followed by scintillation counting. 
Each assay was done in quadruplicate,  and the results are given 
as the mean. 
Cytokine Assays 
Preparation and Treatment  of  Human Monocytes.  PBMC were ob- 
tained by centrifugation on Ficoll (MSL; Eurobio, Les Ulis, France) 
of 1:2 diluted heparinized venous blood from healthy adult volun- 
teers. Monocytes were selected by allowing the mononuclear ceUs 
to adhere to plastic culture dishes (24 wells; Nunc, Roskilde, Den- 
mark) in the absence of serum (37).  More than 85% of the ad- 
herent cells were monocytes, as assessed by morphological analysis 
by phase-contrast microscopy, histochemical staining for nonspecific 
esterase activity (38),  and indirect  immunofluorescence staining 
using antilymphocyte antibodies,  OKTll (Ortho Diagnostics, Inc., 
Raritan, NJ) and IOBI (Immunotech, Marseille,  France). Human 
mononuclear adherent cells (5  x  10  s nonspecific esterase-positive 
cells per well), cultured in RPMI 1640 medium (Gibco Laborato- 
ries,  Grand Island, NY) supplemented with 100 IU of penicillin 
per ml and 100/~g of streptomycin per ml, were incubated for 24 h 
in the presence of free LPS,  or in the presence of LPS that had 
been incubated previously with dilutions of anti-lipid A antibodies 
or 2/~g/ml polymyxin B for I h at 37~  in culture medium con- 
taining 3.3% decomplemented normal human serum. These solu- 
tions were then added to the cells so that the final serum concen- 
tration in all cultures was 0.2%. Final reaction mixtures contained 
the indicated amounts of antibody and LPS in a volume of 0.5 ml 
per well. Culture supernatants were collected and centrifuged at 
3,000 g  for 15 min and assayed for cytokines.  II.,1 found in the 
supernatant will be referred to as IL-1 or released IL-1. The adherent 
cells were then lysed by three freeze-thaw cycles in 0.5 ml of fresh 
RPMI 1640 medium, and the lysates  were centrifuged at 3,000 
g for 15 min. The II.,1 found in these supernatants will be referred 
to as cell-associated  IL-1, 
Whole Blood Cytokine Assays.  The induction of cytokines by 
LPS in whole blood was measured as described (39). Briefly, 500 
/~1 blood diluted 1:5 in RPMI-1640 culture medium per well was 
cultured in the presence of free LPS, or LPS that had been prein- 
cubated with antibodies  or polymyxin B. Preincubations (LPS alone 
or with antibodies or polymyxin B) were performed in the pres- 
ence of 3.3% decomplemented normal human serum as described 
above. Final reaction mixtures contained the indicated amounts of 
antibody and LPS, Cytokines were assayed after 24 h of culture. 
TNF Assay.  An ILIA specific for TNF-ot was performed ac- 
cording to Munoz et al.  (37)  with minor modifications. Briefly, 
on day 1,  100 #1 of a rabbit anti-TNF-c~ antiserum (a kind gift 
of Catherine Rougeot, Institut Pasteur) diluted ~:8,200 to precipi- 
tate 35% of the radiolabded TNF was added to 100/zlof standards 
or samples.  To determine the nonspecific binding,  100/~1 of BSA 
buffer was added to a tube instead of sample. Then 300/zl of BSA 
buffer was added to each tube. After vortexing, the tubes were in- 
cubated for 24 h at room temperature. Standards of TNF-a (Rhone 
Poulenc, Vitry-sur-Seine, France) containing 0, 40, 80,  150, 300, 
600,  1,250,  2,500,  5,000,  and 10,000  pg/ml were employed. On 
day 2,  100/~1 of a solution of uSI-TNF-ol (30/zCi/#g,  New En- 
gland Nuclear, Boston, MA) containing =10,000 cpm was added 
to each tube. The tubes were vortexed and incubated at room tem- 
perature for 24 h. On day 3, 500/~1 of BSA buffer containing 6% 
of polyethylene glycol 8000 (Sigma Chemical Co.),  1% of horse 
anti-rabbit IgG, and 0.1%  of normal rabbit serum were added. 
The tubes were vortexed and incubated for 2 h at 4~  The tubes 
were then centrifuged at 1,500 g for 15 min at room temperature. 
Thereafter, the supernatants were discarded and the tubes were kept 
inverted for 30 min and drained on absorbent paper. Tubes were 
counted in a gamma counter, and the value for nonspecific binding 
was subtracted. All standards and samples were expressed as per- 
cent standard containing no TNF-o~ (zero standard). The concen- 
trations of TNF-ot in pg/ml on a logarithmic x-axis were plotted 
against the binding percentage on a logarithmic y-axis. The stan- 
dard curve obtained was used to determine the concentrations of 
TNF-c~ in samples.  The detection limit was 70 pg/ml. 
11,I Assay.  A  similar ILIA protocol as that used for TNF-c~ 
measurement was employed to determine concentrations of ID1B. 
Standard IL-1B  was obtained from Rhone Poulen~ Rabbit anti-IZ-13 
antisermn (1:150) was purchased from Endogen, Inc. (Boston, MA), 
and 12sI-IL-1B (126-253  (/zCi//zg)  was obtained from New En- 
gland Nuclear.  On day 3,  500 #1 of BSA buffer containing 6% 
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Chemical Co.),  and 0.05%  normal rabbit serum were added to 
each tube. Determination of IL-1B concentrations in plasma and 
samples were calculated as described above. The detection limit was 
70 pg/ml. 
The IL-lct concentrations were determined by ELISA using two 
anti-IL-lt~ mAbs as described (37).  Briefly, on day 1, ELISA mi- 
crotiter plates (Maxisorp; Nunc, Roskilde, Denmark) were coated 
with 100/zl of monoclonal mouse IgG1 anti-rhlblot  (10/~g/ml 
in carbonate buffer) and incubated 2 h at 37~  The plates were 
washed three times with 0.1% Tween 20 PBS. Standards (0, 10, 
30, 300, 1,000, 3,000, and 10,000 pg(ml rhlblt~) or cell superna- 
tant or cell lysate samples diluted in 1% BSA, 0.1% Tween 20 PBS 
were added to coated wells  and incubated overnight at 4~  On 
day 2, the plates were washed three times and 100/zl of the second 
monoclonal  mouse  anti-rhlI~lc~  (IgG2b)  (1:2,000  in 
BSA/Tween/PBS) were added into each well. Plates were incubated 
for 3 h at 37~  After washing,  100 #1 of peroxidase-conjugated 
anti-mouse lgG2b (1:5,000)  (Southern Biotechnology Associates, 
Inc., Birmingham, AL) were added to each well and the plates were 
left for 1 h  at 37~  After washing,  enzymatic activity was de- 
tected with a phosphate citrate buffer containing 1 mg/ml O-phenyl- 
enediamine dihydroxychloride (Sigma Chemical Co.) and hydrogen 
peroxide (0.06%). The reaction was stopped with 50/zl of3N HC1, 
and the absorbance was read at 492 nm on a microplate reader 
(Titertek multiskan MC340; Flow Laboratories, Inc., McLean, VA). 
The levels of II-lct in the samples were calculated by reference to 
the standard curve. The detection limit of Iblot was 30 pg/ml. 
11.,6 Bioassay.  IL-6 activity was determined as described (37) 
by using the specific 7TD1  IL-6-dependent cell line (40)  kindly 
provided by D~ J.  Van Snick (Ludwig Institute for Cancer Re- 
search, Brussells, Belgium). Cells were cultured at a density of 1,200 
cells/well (96-well multidish plates; Falcon Labware, Oxnard, CA) 
in 100/zl of RPMI medium supplemented with antibiotics, 2-ME 
(5  x  10 -s M) and 10%  FCS,  in the presence of serial dilutions 
of cell supernatants, After 4 d of culture at 37~  the proliferation 
was monitored by a dye method.  Briefly,  125/zg of tetrazolium 
salts (MTT) were added to each well and after 1-2 h of incubation 
at 37~  the reaction was stopped with 100/zl/well of an extrac- 
tion buffer (20%  SDS,  50%  DMF,  2.5%  1.0 N  HC1, 2.5%  of 
80% acetic acid, pH 7.4). After overnight incubation at 37~  OD 
were measured at 540 nm using an automated microELISA au- 
toreader. One unit of Ib6 corresponds to half-maximum growth 
of the hybridoma cells.  IL-6 activity detected in supernatants of 
LPS-stimulated monocytes and in plasma was completely abolished 
by the addition of 10/zg rabbit polyclonal anti-human Ib6 anti- 
bodies (Genzyme Corp.,  Boston,  MA). 
Results 
Bi.ding of HA.IA a.d ES to FH~.~S.  At a concentration 
of 200/zg/ml,  HA-1A consistently bound slightly more ra- 
diolabeled LPS in comparison to controls (Table 1).  In two 
instances (E. coli O1 and E.  coli O2),  substantial  quantities 
of radiolabeled LPS were bound by HA-1A, but  these LPS 
were bound considerably by control polyclonal human and 
mouse IgM/HSA as well. In contrast, there was little or no 
difference in the amount of LPS bound by E5 compared to 
controls  (Table  1).  We  varied  the  concentration  of mAbs 
to compare binding with  the  O-specific IgG antibody and 
to see if higher concentrations of anti-lipid A  mAbs would 
be more efficient at binding.  These results are shown in Fig. 
1. At very high concentrations  (1.6 mg/ml),  E5 bound up 
to 30%  of the LPS from certain strains, which was slightly 
higher than the polyclonal IgM control in this series of ex- 
periments, whereas HA-1A bound somewhat less. As expected, 
the O-specific IgG mAb bound homologous LPS efficiently 
at low concentrations (half-maximal binding at 5-10 ~g/ml). 
Neutralization of LPS as Assessed by Liraulus L2/sate.  A rep- 
resentative experiment  assessing the  ability of HA-1A  and 
E5 to neutralize LPS in the limulus lysate assay is shown in 
Fig. 2 using LPS from rough mutant E. coliJ5. Neither anti- 
body inhibited the activity of LPS over a wide range of LPS 
concentrations.  In additional experiments (data not shown), 
LPS from smooth strains E. coli O18, E. coli Ol13, and E. coli 
Ol11:B4,  and rough  strain N.  meningitidis were tested.  No 
neutralization of LPS by either mAb was observed. Each ex- 
Table  1.  Percentage of ffHILPS Bound  by Different Ig Preparations at 200 Itg/ml* 
[3H]LPS  Anti-E.  coil  Polyclonal  Human IgM  Polyclonal 
(5  /x/ml)  PBS/HSA  0111:B4/HSA  Human IgM/HSA  myeloma/HSA  HA-1A/HSA  Mouse IgM/HSA  E5/HSA 
E. coli 01  3.8  _+  3.3  1.5  +_  0.7  9.7  _+  2.1  7.5  _+  3.5  26.2  +  10.4  23.0  _+  0.0  11.0  +  1.4 
E.  coli 02  3.5  +_  3.5  1.0  -+ 0.0  42.0  _+  18.3  3.5  -+  2.1  60.7  +  22.4  59.5  +  3.5  8.0  +  1.4 
E.  coli 04  2.5  +  1.2  2.0  _+  1.4  5.0  +  0.0  4.0  +  1.4  15.1  _+  8.7  7.5  _+  3.5  5.0  +_  0.0 
E.  coli 06  1.2  +  0.4  1.5  +_  0.7  2.0  +  0.0  2.0  +_  0.0  7.5  _+  3  6.5  +  6.4  4.0  _+  1.4 
E.  coli 07  1.3  _+  0.7  1.0  _+  0.0  1.5  _+  0.7  1.5  _+  0.7  10.5  +  7.4 
E.  coli 08  1.8  _+  1.1  1.0  -+ 0.0  2.0  _+  1.4  3.0  +- 0.0  13.0  +_  3.6 
E.  coli 018  1.4  +_ 0.7  1.0  _+  0.0  2.0  _+  0.0  1.5  +  0.7  9.8  +  6.7 
E. coli 025  2.0  +  1.2  1.0  _+  0.0  7.0  _+  6.2  2.5  -+ 0.7  16.1  +_  9.2  3.0  -+ 0.0  1.6  +_  0.5 
E.  coli 075  2.1  +_  1.7  1.5  _+  0.7  6.0  +  4.3  1.5  +_  0.7  11.2  _+  5.5  5.5  +  2.1  3.6  _+  2.1 
E.  coli 0111:B4  6.4  _+  5.8  65.0  _+  15.0  4.0  _+  1.4  5.0  _+  1.4  23.2  +  8.5  3.0  +_  0.0  6.5  +  7.8 
* Each value represents mean  _+ SD. 
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Figure 3.  Effect of HA-1A (left) and E5 (right) on 
LPS-induced mitogenic activity on splenocytes. Wells 
contained indicated amounts of LPS from E. coli O18 
and 25 ~g antibody or 2 ~g polymyxin B or PBS. 
periment was repeated three times for each LPS and each an- 
tibody. 
Neutralization of LP8 as Assessed by Splenocyte Mitogenic 
Assay.  LPS from smooth strains E. coli018 and E. coli Ol13, 
and rough strains E. coli  J5 and N. raeningitidis were tested. 
Neither HA-1A nor E5 inhibited the activity of any of the 
LPS  tested  for  mitogenicity.  In  contrast,  polymyxin  B 
abrogated the mitogenic effects of LPS over a wide range of 
LPS concentrations.  A  representative experiment  is shown 
in Fig.  3.  Each experiment was performed three times for 
each anti-lipid A  antibody. 
Neutralization of LPS as Assessed by Induction of Cytokines 
from Monocytes.  In this series of experiments,  dilutions  of 
LPS were preincubated with differing  concentrations of HA-LA 
and E5 and then exposed to cultured human monocytes  or 
incubated in whole blood. The induction of TNF, Ibl, and 
IL-6 by these  mixtures  was  then  assessed as  described in 
Materials and Methods.  LPS  from  smooth  strains E.  coli 
Ol11:B4 and E. coli O18, and rough strains E. coli  K12, D31m4 
(Re), E. coli  JS, and N. meningitidis were tested. HA-1A and 
E5 had no significant effect on the induction  of TNF, Ibl, 
or IL-6 in the two types of assay system. Representative ex- 
periments for HA-1A for the adherent cell system (n  =  5) 
and the whole blood system (n  =  7) are shown in Figs. 4 
and 5, respectively. Representative experiments for E5 (n  = 
2, adherent ceUs; n =  4, whole blood) are shown in Fig. 6. 
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These studies demonstrate that anti-lipid A mAbs HA- 
1A and E5 bind only weakly to LPS from multiple clinically 
relevant smooth gram-negative bacteria,  and are unable to 
neutralize the biological effects  of  LPS in several  in vitro assays. 
Our findings do not support the hypothesis that either of 
these antibodies is able to protect patients with gram-negative 
sepsis by binding to lipid A and blocking the toxic effects 
of endotoxin in the bloodstream. 
Each of these mAbs have been described to bind to lipid 
A and LPS as assessed by ELISA (15, 41), although a more 
recent abstract suggested that HA-1A binds only slightly to 
smooth LPS using this technique (42). Since solid-phase  assays 
using LPS are difficult to interpret because of nonspecific 
binding to the solid-phase matrix, we used a fluid-phase ILIA 
to measure antibody-LPS binding. We found that both HA- 
1A and E5 bound to radiolabeled smooth LPS compared to 
irrelevant IgM controls, but that it was necessary to use very 
high concentrations  of IgM to see the effect. We were un- 
able to achieve half-maximal binding of any of the bacterial 
strains tested even with 1.6 mg/ml HA-1A or E5, whereas 
half-maximal binding of E. coli Ol11:B4 LPS was achieved 
at 5-10/~g/ml of an IgG mAb six,tic for the O-polysaccharide 
of this LPS. The RIA that we used was initially described 
by Farr  (34), and depends  upon the precipitation  of an- 
tigen-antibody complexes in 50% ammonium sulfate while 
free antigen remains in solution.  We were not able to assess 
binding of either antibody to rough LPS from E. coli  J5 be- 
cause we found that >90% of this LPS is precipitated by 50% 
ammonium sulfate. Since high concentrations of HA-1A and 
E5 were needed to precipitate LPS, we cannot exclude the 
possibility that some or all of the binding that we measured 
at high antibody concentrations is nonspecific. It has been 
suggested that anti-core glycolipid antibodies may interact 
with LPS in a nonspecific manner through hydrophobic in- 
teractions (43). Indeed, we found that some of the control 
antibody preparations bound appreciable quantities  of LPS 
at high concentrations. 
There is no previously published information on the ability 
of these two anti-lipid A antibodies to neutralize the biolog- 
ical effects of LPS. We investigated the ability of the mAbs 
to inhibit LPS-induced activation in the limulus lysate assay 
and proliferation of routine splenocytes.  Lipid A plays a major 
role in each of these assays (44). In addition, we studied the 
capacity  of the mAbs  to  prevent  LPS-induced  monocyte 
production of IL-1, IL-6, and TNF.  I/.-1 and TNF are felt 
to be important in the pathogenesis of septic shock (45-50), 
and plasma levels of TNF and Ib6 have  been reported to corre- 
late with the outcome of patients with sepsis (51-54). Nei- 
ther HA-1A nor E5 was able to neutralize the effects of LPS 
in any of the assays we used, even when the antibodies were 
preincubated in excess  with LPS from rough bacterial strains. 
Our results need to be viewed with some caution. All of 
the experiments were performed with LPS that had been ex- 
tracted chemically. It is possible that the mAbs would bind 
better to bacterial membrane fragments. Recently, data have 
been presented in abstract form that HA-1A binds to gram- 
negative bacteria that have been previously treated with anti- 
biotics that are active against the bacterial cell wall (42). In 
addition, it is possible that we would have found more binding 
or some neutralization if we had used even higher concentra- 
tions of antibody in our assays. Nevertheless, the concentra- 
tions used in the binding assay are greater than physiologic, 
and the ratio of antibody to LPS in the neutralization  assays 
that we used for the LAL, mitogenic assay, and cytokine assays 
were 106 ,  103 , and 103 by weight. Although molar ratios 
would have "~90-fold less than this based on estimated LPS 
and IgM molecular weights of 10,000 and 900,000, these ratios 
should have been more than adequate to see some evidence 
of neutralization,  especially given that each antibody is pen- 
tameric. Because there are many mediators that contribute 
to the septic syndrome, it is also possible that the weak binding 
that we detected could affect mediators of sepsis other than 
the cytokines we measured, and thereby exert a protective 
effect. Finally, the binding that we detected could lead to 
protection by mechanisms other than neutralization,  such as 
by increasing the clearance of LPS. 
Since E5 and HA-1A may be used clinically on a wide- 
spread basis, further work should be done on their mecha- 
nism(s) of  action. This knowledge could lead to the develop- 
ment of an in vitro test that correlates with protective efficacy 
and might indicate which patients would most benefit from 
these expensive agents. 
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